Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:45:59.295Z.
Calculation as of: 2026-10-06T15:45:59.295Z.
Quote observation: 2026-10-06T15:45:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 953d1456faf84e3d3f88a5480ffc5766df2e412b5fda6c1fb2fa7c75cf2e613b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$353.90M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$354.45M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $335.08M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $332.28M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $339.48M | 11.32% | 6.91% | 6.91% | 10.15% |
| C4 Therapeutics, Inc. (CCCC)vs › | $321.20M | N/A | N/A | N/A | N/A |
| CapsoVision, Inc. (CV)vs › | $319.27M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $318.73M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.90M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $356.26M | 18.57% | 21.70% | 14.93% | 15.13% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $354.45M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $356.17M | N/A | 3.28% | 4.15% | 7.65% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
